SYSTEMATIC REVIEW

The impact of baseline ^{18}F-FDG PET-CT on the management and outcome of patients with gastric cancer: a systematic review

[1]KIERAN G FOLEY, FRCR PhD, [2]WILL COOMER, [3]BERNADETTE COLES and [4]KEVIN M BRADLEY

[1]Division of Cancer & Genetics, School of Medicine, Cardiff University, Wales, United Kingdom
[2]National Imaging Academy of Wales (NIAW), Pencoed, United Kingdom
[3]Velindre University NHS Trust Library & Knowledge Service, Cardiff University, Wales, United Kingdom
[4]Positron Emission Tomography Imaging Centre (PETIC), Cardiff University, Cardiff, United Kingdom

Address correspondence to: Dr Kieran G Foley
E-mail: *foleykg@cardiff.ac.uk*

Objective: CT and staging laparoscopy are routinely used to stage patients with gastric cancer, however the role of ^{18}F-fluorodeoxyglucose (FDG) positron emission tomography (PET) combined with CT (PET-CT) is uncertain. This systematic review synthesised the evidence regarding the impact of baseline PET-CT staging on treatment decisions and patient outcomes.

Methods: Systematic database searches were performed without date restriction. Studies reporting data in patients with gastric adenocarcinoma who underwent radiological staging were included. One reviewer screened titles and abstracts for suitability and two reviewers extracted data from included articles. Primary outcome was the reported change in management after PET-CT. Secondary outcomes were the rates of recurrence and overall survival between patients staged with and without PET-CT. Risk of bias was assessed using the ROBINS-I tool. PROSPERO registration (CRD42022304314).

Results: Data from 11 studies recruiting 2101 patients between 2012 and 2021 were included. PET-CT was performed in 1422 patients. Change of management varied between 3% and 29% of cases. No studies compared recurrence or survival rates between patients staged with or without PET-CT. Adenocarcinoma of intestinal subtype tended to be more FDG-avid compared to diffuse or signet-ring subtypes. No randomised data existed, and studies were considered low quality with high risk of bias.

Conclusion: Evidence for the additional value of PET-CT in the gastric cancer staging pathway is limited. All studies reported a positive impact by preventing those with undetected metastatic disease on CT undergoing futile surgery. Future national guidelines should consider routine staging PET-CT in gastric cancer.

Advances in knowledge: Studies indicated that FDG PET-CT added benefit in gastric cancer staging by detecting more distant metastases, but these studies were generally of low quality and at high risk of bias. Intestinal subtype of gastric adenocarcinoma tended to be more FDG-avid and therefore more distant metastases were subsequently detected.

INTRODUCTION

Despite modest improvements in outcome, the overall survival of patients with gastric cancer remains poor, with 5 year survival estimated as 20%.[1] The incidence of gastric cancer has been declining due to improved detection and treatment of *H. pylori* infections,[2] yet many patients continue to present with metastatic disease which limits available treatment options.[3] Patients are currently offered peri-operative chemotherapy and gastrectomy as standard first-line radical treatment of locally advanced disease.[4]

Current radiological staging pathways rely on staging CT to assess tumour and nodal staging for resectability, and to detect distant metastatic disease, which would preclude any radical treatment.[5] CT has good accuracy for predicting resectability but is known to have suboptimal sensitivity for distant metastatic disease.[3]

Unlike oesophagogastric cancer, where positron emission tomography (PET) is routinely recommended for staging all patients deemed to be potentially curable,[6] the role of ^{18}F-fluorodeoxyglucose (FDG) PET-CT in gastric cancer is less clear. Concerns regarding the FDG-uptake of the primary tumour, sensitivity of distant metastases, cost, and resource availability have limited clinician's confidence in this modality. As such, the Royal College of Radiologists

(RCR) indications for PET-CT use in the United Kingdom (UK), which were published in 2022, lists gastric cancer as one tumour site in which PET-CT can be considered only when management may be changed by the result.[7] Thus, a few UK centres offer PET-CT for gastric cancer staging, however the majority do not.

Staging PET-CT should be made available to all gastric cancer patients if there is evidence of improved clinical outcomes. PET-CT has the potential to reduce the number of patients that undergo futile gastrectomy, which is associated with significant co-morbidity, when distant metastatic disease is undetected on CT. However, the evidence concerning the impact of PET-CT on treatment decisions has not been systematically reviewed before.

Therefore, this review aimed to systematically search the literature and synthesise the evidence concerning the role of baseline staging PET-CT in gastric cancer staging. The primary aim was to determine how frequently PET-CT changes patient management by detecting additional disease. The secondary aims were to assess whether PET-CT changed recurrence or survival rates in patients with gastric cancer.

METHODS AND MATERIALS
This study is reported according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA)[8] and Synthesis Without Meta-Analysis (SWiM)[9] guidelines. This systematic review is registered with PROSPERO (CRD42022304314).

Search strategy and selection criteria
The MEDLINE [OVID], Embase [OVID], Cochrane Library [Wiley], Scopus [Elsevier], Web of Science Core Collection [Clarivate], Cumulative Index of Nursing and Allied Health Literature (CINAHL) [Ebsco], ClinicalTrials.gov, and World Health Organisation (WHO) databases were systematically searched on 25 November 2021. The search strategy was devised using Medical Subject Headings (MeSH) and free-text terms relating to gastric cancer and PET and adapted using the rules and syntax of the other databases. The search was limited to the English language and without date restriction. No filters for study design were applied. A grey literature search was not performed. The full search strategy can be found in Appendix 1.

Inclusion criteria for studies were: (1) patients with confirmed histological cell type of adenocarcinoma or signet-ring carcinoma, (2) patients who underwent radiological staging, (3) patients who received either chemotherapy followed by surgery, surgery alone, or palliation, and (4) sufficient follow-up (at least 12 months) to determine clinical outcomes of recurrence and survival.

The Lauren classification[10] describes intestinal *vs* diffuse and indeterminate sub-types of gastric adenocarcinoma. The World Health Organisation (WHO) classification[11] describes papillary, tubular, and mucinous sub-types of adenocarcinomas (which are comparable to the Lauren intestinal sub-type) and signet-ring cell and other poorly cohesive carcinomas (comparable to Lauren diffuse sub-type). In addition, rarer sub-types of gastric carcinoma (*e.g.* mixed, squamous, adenosquamous) are comparable to Lauren indeterminate sub-type. Lauren diffuse and indeterminate sub-types comprise non-intestinal sub-types.[12]

Exclusion criteria were: (1) studies with a mix of primary tumour types where data pertinent to this systematic review could not be extracted, (2) patients with gastric lymphoma or other rare cell types, (3) studies investigating oesophageal or junctional tumours (Siewert Type I and II), (4) studies investigating recurrent gastric cancer, and (5) studies that used any PET tracer other than FDG.

Data collection and extraction
The title and abstracts of studies retrieved during the search process were screened by one reviewer (KGF) for relevance to this systematic review. Full-text articles were retrieved after screening to check against the eligibility criteria. Studies that met the eligibility criteria were included. Data were independently extracted by two reviewers (KGF, WC) from the included articles and inputted into a spreadsheet designed for this review. In cases of disagreement, a consensus was reached after consulting a third reviewer. The data variables that were collected are listed in Appendix 2.

Outcomes
The primary outcome was the effect that PET-CT had on changing initial treatment decision plans. Secondary outcomes were the rates of recurrence and overall survival between patients staged with or without PET-CT.

Risk of bias assessment
Methodological quality of included studies was assessed with the Risk Of Bias In Non-randomized Studies—of Interventions (ROBINS-I) tool.[13]

Statistical analysis
Data from individual studies concerning primary and secondary outcomes were synthesised using summary statistics and confidence intervals, where available, across the cohorts of patients with gastric cancer. Meta-analysis was not performed because few high-quality studies existed. Standardised metrics were used to synthesise the data and are presented in tabular format. The standardised metric for the primary outcome, was the percentage of cases in which PET-CT was perceived to change the patient management plan from that originally intended. Heterogeneity between studies and limitations in quality of evidence were highlighted in tables. Pre-specified subgroup analysis compared the proportion of cases in which distant metastatic disease was found on PET-CT. The approach described by Murad et al[14] to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework[15] was used to rate the certainty in evidence for each outcome.

RESULTS
The systematic search discovered 4637 records, of which 2084 were duplicates. The titles and abstracts of 2553 studies were screened for inclusion. After screening, 2506 studies were excluded leaving 47 full text articles for review.

Figure 1. Study selection process.

19 studies did not report data relevant to the primary outcome of this review,[16–34] 5 reported data in either patient cohorts not relevant to this review or from cohorts with mixed tumour types that could not be extracted,[35–39] 5 had study designs that were not relevant,[40–44] 4 investigated a new technology or novel tracers,[45–48] 2 were not in the English language,[49,50] and 1 was a study protocol[51] (Figure 1).

Overall, 11 observational cohort studies[52–62] were included that reported data from 2101 patients, of whom 1422 had PET-CT. No randomised studies were identified, and no studies reported prospective data with formal documentation of change in individual treatment decisions before and after PET-CT. Further, no studies reported differences in recurrence or survival rates in patients who received PET-CT or not. Table 1 details the important characteristics of the included studies.

Most patients were male ($n = 1,085$, 65.4%). The median ages of the cohorts ranged between 57 and 71 years. Proximal tumours accounted for 249 (11.9%) of gastric cancer patients with the remainder located in the body, antrum, or pylorus. Findlay et al[57] reported that 5.0% of patients had linitis plastica, but no other

studies commented on the incidence of this pathology. Table 2 details characteristics of the PET-CT examination and scanner type in each study.

Five studies[52,54–56,59] reported a sub-group of patients with signet ring morphology, ranging from 10 to 32% of their cohorts. Six studies reported the Lauren classification.[53,57,58,60–62] Of the 1249 patients reported, there were similar distributions between intestinal ($n = 578$, 46.5%) and diffuse ($n = 581$, 46.5%) Lauren subtypes. Grade of differentiation was classified in 1645 patients. Most adenocarcinomas were poorly differentiated ($n = 1052$, 64.0%).

PET-CT was reported to change management in between 3% and 29% of cases. The largest cohort study,[58] and the only multi-centre study included, reported the lowest proportion of cases (3%) where PET-CT changed the management plan (Table 3).

Comparison of PET-CT with laparoscopy
Six studies[54,56–58,60,62] reported the findings of PET-CT and staging laparoscopy in their cohorts. Debiec et al,[54] Filik et al[56] and Perlaza et al[60] found that nine (8.1%), five (16.1%),

Table 1. Summary of included cohort studies

Author	Year	Country	Study design	Sites	Recruitment dates	Cohort size	Age	Male	Number had PET-CT	Outcomes
Atici et al[52]	2016	Turkey	Prospective	1	2008–2010	31	Median (range) 57 (38–74)	23 (74.2)	31	Change in management
Bosch et al[53]	2020	England	Retrospective	1	2014–2016	330	Median (range) 73 (24–95)	214 (64.8)	105	Change in management
Debiec et al[54]	2021	Poland	Retrospective	1	2008–2019	111	Median (range) 64 (37–85)	79 (71.2)	111	Change in management
Duman et al[55]	2013	Turkey	Prospective	1	2005–2007	30	Median (range) 61 (35–80)	22 (73.3)	30	Change in management
Filik et al[56]	2015	Turkey	Retrospective	1	2011–2012	31	Mean (SD) 58.9 (12.6)	24 (77.4)	31	Change in management
Findlay et al[57]	2019	England	Retrospective	1	2007–2016	279	Median (IQR) 71 (62.3–78.0)	185 (66.3)	279	Change in management
Gertsen et al[58]	2021	Netherlands	Prospective	18	2017–2020	394	Mean (SD) 67.6 (10.7)	256 (65.0)	382	Change in management
Li et al[59]	2012	China	Retrospective	1	2007–2011	124	NR	92 (74.2)	124	Change in management
Perlaza et al[60]	2018	Spain	Prospective	1	2010–2011	50	Mean (SD) 65.7 (12.1)	30 (60.0)	50	Change in management
Serrano et al[61]	2016	USA	Retrospective	1	2006–2014	608	Median (range) 67 (29–94)	92 (55.4)	166	Change in management
Smyth et al[62]	2012	USA	Prospective	1	2003–2010	113	Median (range) 61 (25–83)	68 (60.2)	113	Change in management

IQR, interquartile range; NA, not reported; SD, standard deviation.

Table 2. Characteristics of the PET-CT examination in each study

Author	PET-CT scanner type	Dose	Length of fasting before injection (mins)	Interval between injection and scan (min)
Atici et al[52]	Siemens Biograph mCT 64	296–703 MBq	360	60
Bosch et al[53]	GE Discovery 710	350 MBq (283–389)	NR	90
Debiec et al[54]	Siemens Biograph mCT Philips Gemini XL	185–555 MBq	360	60 ± 10
Duman et al[55]	Siemens ECAT EXACT	370–555 MBq	480	60
Filik et al[56]	GE Discovery ST	8–10 mCi	360	60
Findlay et al[57]	Pre 2009: GE Discovery STE 16-slice After 2009: GE Discovery 690 64-slice From 2014: GE Discovery 710	Before 2009: 400 MBq After 2009: 4 MBq/kg	NR	Before 2009: 60 After 2009: 90
Gertsen et al[58]	Varied (no detail of individual scanners)	NR	240–360	60
Li et al[59]	GE discovery LS	10 mCi adjusted for weight	240	45–60
Perlaza et al[60]	Siemens Biograph mCT 64S	4 MBq/Kg	NR	120
Serrano et al[61]	Philips Gemini TF	5.18 MBq/Kg	>240	60
Smyth et al[62]	Siemens Biograph or GE Discovery LS	NR	>360	60

MBq, megabecquerel; NR, not reported; PET, positron emission tomography;mCi, millicurie.
All patients received ^{18}F-fludeoxyglucose (FDG).

and nine (18.0%) patients had peritoneal disease undetected by PET-CT, respectively. Gertsen et al[58] found that 73 patients (19%) had a positive staging laparoscopy whereas only 3 patients (0.8%) in the whole cohort had FDG-avid peritoneal metastases on PET-CT. Findlay et al[57] found that peritoneal disease was undetected by PET-CT in 35 patients (a false-negative rate of 12.5% and confirmed at laparoscopy), but in 20 patients with PET-positive metastases, 13 patients had peritoneal disease that would not have been identified at laparoscopy. No peritoneal metastases were identified by PET-CT in Smyth et al.[62]

FDG-uptake in primary tumours

All studies reported the number of cases in which the primary tumour was deemed FDG-avid. Bosch et al[53] found that 93% of intestinal type tumours were PET-positive *vs* 78% that were non-intestinal types, with a corresponding difference in SUVmax (14.1 ± 1.3 *vs* 9.0 ± 0.9, mean ± standard error of mean, *p* = 0.005). Similar findings were reported by Findlay et al[57] where the median SUVmax of intestinal tumours was 8.9 (IQR 5.05–15.4) compared with 5.1 (IQR 2.50–8.10) for diffuse type tumours (*p* < 0.001). A large difference in avidity between intestinal and diffuse sub-type tumours was found by Smyth et al[62] (97% *vs* 44%, *p* < 0.0001). Moreover, gastric adenocarcinomas with signet-ring morphology tended to have lower FDG uptake. Significantly lower FDG-uptake was found between signet-ring morphology *vs* papillary (*p* = 0.001) and tubular (*p* = 0.0008) adenocarcinoma subtypes.[60] In Filik et al, the mean SUVmax of adenocarcinomas *vs* signet-ring tumours was 15.16 (3.00–44.60) *vs* 9.90 (5.50–17.70).[56]

Metastatic status associated with Lauren classification

Six studies[53,54,57,60–62] reported the distribution of metastases depending on the Lauren Classification. Findlay et al[57] found in multi-variable analysis that after consideration of laparoscopy, patients with diffuse sub-type were less likely to have metastases overall (OR 0.86 (95% CI 0.35–2.08)), indicating greater incidence of PET-detected metastases with intestinal sub-type, although this was not statistically significant. Similarly, Bosch et al[53] found that in FDG-avid primary tumours, the intestinal sub-type was more likely to have metastases than non-intestinal sub-types (34% *vs* 20%). Also, primary tumours with higher SUVmax (14.6 *vs* 11.2, M1 *vs* M0 stage, *p* = 0.052) were more likely to metastasise.[53] Further, Bosch et al[53] commented that lymph node status prediction was more accurate in intestinal than non-intestinal tumours, though overall sensitivity and specificity was poor (40 and 73%, respectively). Debiec et al[54] reported that the risk of false-negative PET-CT for distant metastases was significantly higher for diffuse (37.5%) and signet ring (28.6%) sub-types than for intestinal sub-types (7.5%; X^2 = 8.86, *p* = 0.003). Smyth et al[62] found that peritoneal disease was more likely to be detected by laparoscopy than PET-CT in diffuse gastric cancer (87.5% *vs* 12.5%, *p* = 0.004).

Risk of bias assessment

All studies were deemed at high risk of bias after evaluating each of the seven domains within the ROBINS-I tool. Further detail regarding the risk of bias assessments is included in Appendix 3.

Table 3. Studies reporting the primary outcome of change in management by PET-CT

Author	Recruitment	≥T3 (%)	≥N1 (%)	PET M1	Change of management	Proportion of FDG-avid tumours	How treatment changed
Atici et al[52]	Prospective	18/31 (58.1)	12 (38.7%)	9 (29.0%)	9/31 (29.0%)	29 (93.5%)	Two from medical treatment to surgery; seven from surgery to medical treatment
Bosch et al[53]	Retrospective	NR	NR	27 (26%)	20/105 (19%)	90 (85.7%)	Became palliative with M1 disease. Upstaged N-stage in three and M-stage in 17
Debiec et al[54]	Retrospective	82 (74%)	79 (71%)	51 (46%)	13/111 (11.7%)	99 (89.2%)	Less aggressive treatment was used as result of PET-CT
Duman et al[55]	Prospective	8 (26%) *T4 only	17 (56.7%)	4 (13.3%)	2/30 (6.7%)	27 (90%)	Changed stage and surgical procedure
Filik et al[56]	Retrospective	19/31 (61.3)	13 (41.9%)	6 (19.4%)	4/31 (12.9%)	26 (87%)	6 patients had distant FDG uptake. 4 of 6 were not operated on
Findlay et al[57]	Retrospective	219/279 (78.5) *T2-4	136 (48.7%)	40 (14.3%)	20/279 (7.2%)	225 (80%)	26/279 (9.3%) of PET metastases were unsuspected on CT. Of those 26, they were unequivocal in 12 (4.3%) and indeterminate in 14. 20 PET metastases unsuspected on CT confirmed in total.
Gertsen et al[58]	Prospective	357/394 (90.6)	211 (53.6)	16 (6.8%)	12/394 (3%)	302 (79%)	Curative to palliative
Li et al[59]	Retrospective	77/124 (62.1)	84 (67.7%)	47 (37.9%)	31/124 (27.4%)	112 (90.3%)	Surgery to CRT or palliation in 34/124 (27.4%)
Perlaza et al[60]	Prospective	35/50 (70.0)	16 (32.0)	15 (30.0)	12/50 (24%)	44 (88.0%)	To avoid laparoscopy and/or futile surgical treatment. Patients had chemoradiation.
Serrano et al[61]	Retrospective	52.4% (Stage III or more)	NR	NR	31/166 (18.9%)	125 (75.8%)	PET upstaged in 31 (18.9%) and downstaged in 17 (10.3%)
Smyth et al[62]	Prospective	112 (99%)	70 (62%)	NR	11/113 (9.7%)	76 (67.3%)	Spared futile surgery

FDG, fludeoxyglucose; *M*, M-stage; *N*, N-stage; *NR*, not reported; PET, positron emission tomography; *T*, T-stage.

GRADE assessment

The certainty in evidence for the primary outcome was rated as low quality for each study according to the GRADE framework (Appendix 4).

DISCUSSION

Disease recurrence in patients with gastric cancer is common following gastrectomy. More than 30% of patients have recurrence within 3 years of curative resection, and the majority (88%) have distant metastases,[63] which impacts on overall survival and quality of life. Distant metastatic disease precludes curative treatment in current UK practice. National data have reported a benefit of hepatectomy for gastric cancer liver metastases in retrospective analyses for 1 year (35.9% *vs* 50.0 %, *p* = 0.049) and 5 year mortality (61.5% *vs* 75.7 %, *p* = 0.031) *vs* no hepatectomy.[64] However, radical treatment of oligometastatic disease is not performed routinely in clinical practice at present. Selection for gastrectomy must improve to optimise patient outcome and experience in a group of patients who historically have poor survival.[1]

This systematic review has comprehensively summarised the evidence regarding the impact that PET-CT has on patient management in eligible studies. The proportion of cases in which PET-CT changed management varied considerably across studies, ranging from 3%[58] to 29%.[52] Overall, the proportion of cases where PET-CT was reported to change management tended to be lower in studies with larger cohort sizes, although heterogeneity of data was noted across the included studies.

Despite all studies being graded as low-quality based on methodological limitations and risk of bias assessment, the Dutch PLASTIC study was the only prospective and multi-centre study.[58] The PLASTIC study investigated the additional value of PET-CT and staging laparoscopy in patients with potentially curable locally advanced gastric cancer and change of management was the primary outcome. PLASTIC recruited 394 patients, of which 384 had PET-CT, and 357 had staging laparoscopy, and reported that 3% and 19% of patients had distant metastatic disease detected by PET-CT and laparoscopy, respectively.

Overall, the specificity of PET-CT for distant metastases is good, with reported values ranging between 86.5%[54] and 100%[60] in the studies included in this systematic review. However, the sensitivity of PET-CT varied considerably between studies from as low as 25%[52]–76.5%.[54] A recurring limitation of the included studies was a lack of robust pathological reference standard in all patients. This is a limitation of many diagnostic test accuracy studies investigating distant metastatic disease. It would be unethical to subject all patients to an invasive biopsy with potential risk of harm to confirm a pathological diagnosis of metastasis that was highly suspected on imaging. Absence of abnormality on imaging will contribute to the true- and false-negative imaging rates, which in turn will affect the estimates of sensitivity and specificity.

No randomised data were available for PET-CT in this patient group, and generally, study quality was hindered by a high risk of selection bias, lack of pathological validation, limited clinical follow-up, and absence of documented management change. The evidence for PET-CT use in patients with gastric cancer remains limited.

Routine use of staging PET-CT in gastric cancer may avoid subsequent laparoscopy in a small number of patients and could assist the detection of metastases in difficult locations to assess during laparoscopy. Smyth et al[62] hypothesised that if PET-CT were performed first, 11 of 113 (10%) of patients would have avoided a futile laparoscopy. Estimates of the incidence of PET-positive peritoneal disease were generally poorly reported. The main study to describe the benefits of PET-CT *vs* the limitations of laparoscopy was Findlay et al,[57] in which PET identified unsuspected metastases in 20 patients (7.2%), in locations notoriously difficult to assess at laparoscopy, such as the lesser sac, and extra-abdominal sites.

Staging laparoscopy is not without limitations. The sensitivity and specificity of detecting macroscopic peritoneal metastases was 82% (95% CI 70–91%) and 78% (95% CI, 73–83%) in the PLASTIC study.[58] Overall, it remains highly likely that clinicians will elect to continue routine use of staging laparoscopy in locally advanced disease, even after PET-CT, as several studies highlighted the high false-negative rate of PET-CT for peritoneal metastases. All six observational studies reported cases of peritoneal cases not detected by PET-CT.[54,56–58,60,62] Staging laparoscopy will continue to be beneficial, particularly in the diffuse sub-type, because metastases too small to be resolved by PET are common in anatomical locations that also often abut FDG-avid structures such as liver or bowel.

There was considerable heterogeneity in the overall proportions of primary tumours that were FDG-avid ranging from 67.3%[62] to 93.5%.[52] Differences in FDG uptake between sub-types of adenocarcinomas have implications for the detection of distant metastatic disease. Results from included studies indicated that intestinal type gastric adenocarcinomas tend to demonstrate higher FDG uptake than non-intestinal subtypes, are more likely to metastasise, and that those metastases are more likely to be detected on PET-CT. Smyth et al[62] reported that metastatic disease in patients with diffuse gastric cancer was more likely to be detected by laparoscopy (87.5%) than PET-CT (12.5%).

No studies reported the differences in recurrence or survival rates between patients who had staging PET-CT *vs* those who did not. Whilst a staging investigation is unlikely to directly influence these important outcomes, PET-CT may improve patient selection for radical treatment, and therefore improve overall outcomes. For instance, Findlay et al[57] found that PET refuted metastases suggested on CT in five patients (1.79%). The clinical effectiveness of staging PET-CT in gastric cancer therefore remains unknown.

The PLASTIC study reported the numbers of incidental findings found by staging PET-CT.[58] Of 382 patients in total, a clinically relevant lesion was found in 83 (22%) of the 132 patients with suspected relevant secondary findings, which resulted in

additional investigations in 60 patients. A second primary tumour was confirmed in 7 of these 83 patients, although follow-up was not reported in the majority. Detection of incidental findings can introduce further delays into the staging pathway, which is important to be aware of. The PLASTIC study found that the introduction of staging PET-CT increased the length of staging pathway from 17 to 19 days.[58]

Few health economic data were reported in the included studies. Of direct relevance to the NHS, Findlay et al[57] estimated that the net additional cost of PET-CT was £322.01 per patient and cost £6910.86 to avoid one futile attempt at radical treatment. Although only one, single-centre study, this suggests that PET-CT could be a cost-effective staging investigation. Data from an American healthcare system were reported in Smyth et al[62] who concluded that if PET-CT was performed prior to laparoscopy, an additional saving of $2000 per patient could be made by reducing the need for laparoscopy in those with biopsy-proven metastatic disease.

This systematic review has synthesised the literature describing the impact of staging PET-CT on the management of patients with gastric cancer. An extensive literature search using robust methodology ensured all relevant studies reporting data pertinent to the aims of the review were captured. However, this systematic review also has some limitations. One reviewer screened the titles and abstracts of identified records for suitability. Meta-analysis was not performed because of the low-quality studies and heterogenous distribution of proportions reported within them. Study design and methodology was generally deemed to be low quality. Publication bias was not assessed but all studies reported a positive effect of PET-CT on change in management. Most studies were single-centre, retrospective in nature, and lacked sufficient detail documenting the treatment decisions made before and after PET-CT. In addition,

some PET-CT scanners used during the study periods were non-time-of-flight, which results in less sensitivity and resolution of current PET scanners. Advances in digital PET technology, improved reconstruction, motion correction and the use of artificial intelligence techniques are likely to increase the diagnostic yield of small foci of disease, such as those commonly found in lymph nodes, the peritoneum, and liver.[65,66] Therefore, the benefits of PET-CT will increase as smaller metastases are accurately detected. Future studies should aim to prospectively document treatment decisions before and after the intervention of PET-CT. Prospective studies, ideally with randomisation, should compare patient outcomes between groups who receive and do not receive PET-CT to estimate its true clinical effectiveness.

In conclusion, this systematic review has shown that evidence concerning the effectiveness of baseline PET-CT in the staging pathway of patients with gastric cancer is lacking and has identified a gap in knowledge where future research should be targeted. Several observational studies have shown that PET-CT influences management by changing treatment decisions in differing proportions of patients. Future national guidelines should consider the routine use of PET-CT in gastric cancer staging given the importance of preventing futile radical surgery.

REFERENCES

1. GBD 2017 Stomach Cancer Collaborators. The global, regional, and national burden of stomach cancer in 195 countries, 1990-2017: a systematic analysis for the global burden of disease study 2017. *Lancet Gastroenterol Hepatol* 2020; **5**: S2468-1253(19)30328-0: 42–54: . https://doi.org/10.1016/S2468-1253(19)30328-0

2. Herrera V, Parsonnet J. Helicobacter pylori and gastric adenocarcinoma. *Clin Microbiol Infect* 2009; **15**: 971–76. https://doi.org/10.1111/j.1469-0691.2009.03031.x

3. Kwee RM, Kwee TC. Modern imaging techniques for preoperative detection of distant metastases in gastric cancer. *World J Gastroenterol* 2015; **21**: 10502–9. https://doi.org/10.3748/wjg.v21.i37.10502

4. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJH, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. *N Engl J Med* 2006; **355**: 11–20. https://doi.org/10.1056/NEJMoa055531

5. Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. *Ann Oncol* 2022; 01851–58: . https://doi.org/10.1016/j.annonc.2022.07.004

6. Obermannová R, Alsina M, Cervantes A, Leong T, Lordick F, Nilsson M, et al. Oesophageal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. *Ann Oncol* 2022; 01850–56: . https://doi.org/10.1016/j.annonc.2022.07.003

7. Royal College of Radiologists. Evidence-based indications for the use of PET-CT in the United Kingdom. 2022. Available from: https://www.rcr.ac.uk/publication/evidence-based-indications-use-pet-ct-united-kingdom-2022

8. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009; **6**(7): e1000097. https://doi.org/10.1371/journal.pmed.1000097

9. Campbell M, McKenzie JE, Sowden A, Katikireddi SV, Brennan SE, Ellis S, et al. Synthesis without meta-analysis (swim) in systematic reviews: reporting guideline. *BMJ* 2020; **368**: l6890. https://doi.org/10.1136/bmj.l6890

10. LAUREN P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. *Acta Pathol*

Microbiol Scand 1965; **64**: 31–49. https://doi.org/10.1111/apm.1965.64.1.31

11. Fléjou J-F. Who classification of digestive tumors: the fourth edition. *Ann Pathol* 2011; **31**: S27–31. https://doi.org/10.1016/j.annpat.2011.08.001

12. Berlth F, Bollschweiler E, Drebber U, Hoelscher AH, Moenig S. Pathohistological classification systems in gastric cancer: diagnostic relevance and prognostic value. *World J Gastroenterol* 2014; **20**: 5679–84. https://doi.org/10.3748/wjg.v20.i19.5679

13. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. *BMJ* 2016; **355**: i4919. https://doi.org/10.1136/bmj.i4919

14. Murad MH, Mustafa RA, Schünemann HJ, Sultan S, Santesso N. Rating the certainty in evidence in the absence of a single estimate of effect. *Evid Based Med* 2017; **22**: 85–87. https://doi.org/10.1136/ebmed-2017-110668

15. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. Grade: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008; **336**: 924–26. https://doi.org/10.1136/bmj.39489.470347.AD

16. Altini C, Niccoli Asabella A, Di Palo A, Fanelli M, Ferrari C, Moschetta M, et al. 18F-Fdg PET/CT role in staging of gastric carcinomas: comparison with conventional contrast enhancement computed tomography. *Medicine (Baltimore)* 2015; **94**(20): e864. https://doi.org/10.1097/MD.0000000000000864

17. Chen J, Cheong J-H, Yun MJ, Kim J, Lim JS, Hyung WJ, et al. Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography. *Cancer* 2005; **103**: 2383–90. https://doi.org/10.1002/cncr.21074

18. Choi JY, Shim KN, Kim SE, Jung HK, Jung SA, Yoo K. The clinical value of 18F-fluorodeoxyglucose uptake on positron emission tomography/computed tomography for predicting regional lymph node metastasis and non-curative surgery in primary gastric carcinoma. *Korean J Gastroenterol* 2014; **64**: 340–47. https://doi.org/10.4166/kjg.2014.64.6.340

19. Gertsen EC, Borggreve AS, Brenkman HJF, Verhoeven RHA, Vegt E, van Hillegersberg R, et al. Evaluation of the implementation of FDG-PET/CT and staging laparoscopy for gastric cancer in the Netherlands. *Ann Surg Oncol* 2021; **28**: 2384–93. https://doi.org/10.1245/s10434-020-09096-z

20. Grabinska K, Pelak M, Wydmanski J, Tukiendorf A, d'Amico A. Prognostic value and clinical correlations of 18-fluorodeoxyglucose metabolism quantifiers in gastric cancer. *World J Gastroenterol* 2015; **21**: 5901–9. https://doi.org/10.3748/wjg.v21.i19.5901

21. Ha TK, Choi YY, Song SY, Kwon SJ. F18-fluorodeoxyglucose-positron emission tomography and computed tomography is not accurate in preoperative staging of gastric cancer. *J Korean Surg Soc* 2011; **81**: 104–10. https://doi.org/10.4174/jkss.2011.81.2.104

22. Hur H, Kim SH, Kim W, Song KY, Park CH, Jeon HM. The efficacy of preoperative PET/CT for prediction of curability in surgery for locally advanced gastric carcinoma. *World J Surg Oncol* 2010; **8**: 86. https://doi.org/10.1186/1477-7819-8-86

23. Kawanaka Y, Kitajima K, Fukushima K, Mouri M, Doi H, Oshima T, et al. Added value of pretreatment (18) F-FDG PET/CT for staging of advanced gastric cancer: comparison with contrast-enhanced MDCT. *Eur J Radiol* 2016; **85**: S0720-048X(16)30076-6: 989–95. : https://doi.org/10.1016/j.ejrad.2016.03.003

24. Kim EY, Lee WJ, Choi D, Lee SJ, Choi JY, Kim B-T, et al. The value of PET/CT for preoperative staging of advanced gastric cancer: comparison with contrast-enhanced CT. *Eur J Radiol* 2011; **79**: 183–88. https://doi.org/10.1016/j.ejrad.2010.02.005

25. Kudou M, Kosuga T, Kubota T, Okamoto K, Komatsu S, Shoda K, et al. Value of preoperative PET-CT in the prediction of pathological stage of gastric cancer. *Ann Surg Oncol* 2018; **25**: 1633–39. https://doi.org/10.1245/s10434-018-6455-0

26. Lim JS, Kim M-J, Yun MJ, Oh YT, Kim JH, Hwang HS, et al. Comparison of CT and 18F-FDG PET for detecting peritoneal metastasis on the preoperative evaluation for gastric carcinoma. *Korean J Radiol* 2006; **7**: 249–56. https://doi.org/10.3348/kjr.2006.7.4.249

27. Ma DW, Kim J-H, Jeon TJ, Lee YC, Yun M, Youn YH, et al. F-Fluorodeoxyglucose positron emission tomography-computed tomography for the evaluation of bone metastasis in patients with gastric cancer. *Dig Liver Dis* 2013; **45**: S1590-8658(13)00062-5: 769–75. : https://doi.org/10.1016/j.dld.2013.02.009

28. Mochiki E, Kuwano H, Katoh H, Asao T, Oriuchi N, Endo K. Evaluation of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer. *World J Surg* 2004; **28**: 247–53. https://doi.org/10.1007/s00268-003-7191-5

29. Mukai K, Ishida Y, Okajima K, Isozaki H, Morimoto T, Nishiyama S. Usefulness of preoperative FDG-PET for detection of gastric cancer. *Gastric Cancer* 2006; **9**: 192–96. https://doi.org/10.1007/s10120-006-0374-7

30. Namikawa T, Okabayshi T, Nogami M, Ogawa Y, Kobayashi M, Hanazaki K. Assessment of (18) F-fluorodeoxyglucose positron emission tomography combined with computed tomography in the preoperative management of patients with gastric cancer. *Int J Clin Oncol* 2014; **19**: 649–55. https://doi.org/10.1007/s10147-013-0598-6

31. Tatar S, Arslan E. The contribution of [18] f-fluoro-2-deoxy-glucose positron emission tomography/computed tomography to the diagnosis and staging of signet-ring cell carcinoma of the stomach. *Biomed Biotechnol Res J* 2021; **5**: 196. https://doi.org/10.4103/bbrj.bbrj_60_21

32. Yeung HWD, Macapinlac H, Karpeh M, Finn RD, Larson SM. Accuracy of FDG-PET in gastric cancer. preliminary experience. *Clin Positron Imaging* 1998; **1**: 213–21. https://doi.org/10.1016/s1095-0397(98)00018-1

33. Yoshioka T, Yamaguchi K, Kubota K, Saginoya T, Yamazaki T, Ido T, et al. Evaluation of 18F-FDG PET in patients with advanced, metastatic, or recurrent gastric cancer. *J Nucl Med* 2003; **44**: 690–99.

34. Youn SH, Seo KW, Lee SH, Shin YM, Yoon KY. 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography: computed tomography for preoperative staging in gastric cancer patients. *J Gastric Cancer* 2012; **12**: 179–86. https://doi.org/10.5230/jgc.2012.12.3.179

35. Aljubran AH, Badran A, Alshaer O, Alhashem H, Omar A, Eldali A. Pattern of use of positron emission tomography/computed tomography (PET/CT) scan in non-colorectal gastrointestinal cancers at KFSHRC, Riyadh, Saudi Arabia. *Egypt J Radiol Nucl Med* 2019; **50**(1). https://doi.org/10.1186/s43055-019-0067-y

36. Hocazade C, Özdemir N, Yazici O, Bozkaya Y, Yazılıtaş D, Toptaş Ş, et al. Concordance of positron emission tomography and computed tomography in patients with locally advanced gastric and esophageal cancer. *Ann Nucl Med* 2015; **29**: 621–26. https://doi.org/10.1007/s12149-015-0985-3

37. Ozkan E, Araz M, Soydal C, Kucuk ON. The role of 18F-FDG-PET/CT in the preoperative staging and posttherapy follow up of gastric cancer: comparison with spiral CT. *World J Surg Oncol* 2011; **9**: 75. https://doi.org/10.1186/1477-7819-9-75

38. Park S, Lee D, Lee KM, Han S-U, Lee JH, Lee SJ, et al. Clinical usefulness of F-18 FDG PET in Lymphoepithelioma-like gastric

carcinoma. *Eur J Radiol* 2017; **94**: S0720-048X(17)30277-2: 160–66: . https://doi.org/10.1016/j.ejrad.2017.06.022

39. Turlakow A, Yeung HW, Salmon AS, Macapinlac HA, Larson SM. Peritoneal carcinomatosis: role of (18) F-FDG PET. *J Nucl Med* 2003; **44**: 1407–12.

40. Arslan E, Aksoy T, Gündoğan C, Şen Ç, Yılmaz Tatar S, Dursun N, et al. Metabolic characteristics and diagnostic contribution of 18F-FDG PET/CT in gastric carcinomas. *Mol Imaging Radionucl Ther* 2020; **29**: 25–32. https://doi.org/10.4274/mirt.galenos.2020.75537

41. Coupe NA, Karikios D, Chong S, Yap J, Ng W, Merrett N, et al. Metabolic information on staging FDG-PET-CT as a prognostic tool in the evaluation of 97 patients with gastric cancer. *Ann Nucl Med* 2014; **28**: 128–35. https://doi.org/10.1007/s12149-013-0791-8

42. Fonocho E, Aydin N, Reddy S, Misra S. Limitations in the use of 18F-FDG PET in the pre-operative staging of gastric cancer: a case series. *Int J Surg Case Rep* 2017; **36**: S2210-2612(17)30237-7: 147–50: . https://doi.org/10.1016/j.ijscr.2017.05.026

43. Kaneko Y, Murray WK, Link E, Hicks RJ, Duong C. Improving patient selection for 18F-FDG PET scanning in the staging of gastric cancer. *J Nucl Med* 2015; **56**: 523–29. https://doi.org/10.2967/jnumed.114.150946

44. Mirza A, Galloway S. Laparoscopy, computerised tomography and fluorodeoxyglucose positron emission tomography in the management of gastric and gastro-oesophageal junction cancers. *Surg Endosc* 2016; **30**: 2690–96. https://doi.org/10.1007/s00464-015-4590-2

45. Jeong J, Cho I, Kong E, Chun K, Jang B, Kim T, et al. Evaluation of hybrid PET/CT gastrography in gastric cancer. *Onkologische Welt* 2013; **04**: 253–59. https://doi.org/10.1055/s-0038-1631532

46. Jiang D, Chen X, You Z, Wang H, Zhang X, Li X, et al. Comparison of [68 GA] GA-FAPI-04 and [18F] -FDG for the detection of primary and metastatic lesions in patients with gastric cancer: a bicentric retrospective study. *European Journal of Nuclear Medicine & Molecular Imaging* 2021; **23**: 23.

47. Liu Y, Zheng D, Liu J-J, Cui J-X, Xi H-Q, Zhang K-C, et al. Comparing PET/MRI with PET/CT for pretreatment staging of gastric cancer. *Gastroenterol Res Pract* 2019; **2019**: 9564627: 1–11: . https://doi.org/10.1155/2019/9564627

48. Qin C, Shao F, Gai Y, Liu Q, Ruan W, Liu F, et al. 68Ga-DOTA-FAPI-04 PET/MR in the evaluation of gastric carcinomas: comparison with 18F-FDG PET/CT. *J Nucl Med* 2021; **16**: 16.

49. Ittrich H, Vashist Y, Rosch T. Staging of gastric cancer. *Endoscopic, Radiological and Laparoscopic Onkologe* 2016; **22**: 371–83. https://doi.org/10.1007/s00761-016-0030-8

50. Staniuk T, Jankowski M, Zegarski W, Małkowski B, Kula Z. Evaluation of the usefulness of FDG-PET/CT in diagnosis and qualification for surgical treatment of advanced gastric cancer. *Wo* 2010; **5**: 302–9. https://doi.org/10.5114/wo.2010.17293

51. Brenkman HJF, Gertsen EC, Vegt E, van Hillegersberg R, van Berge Henegouwen MI, Gisbertz SS, et al. Evaluation of PET and laparoscopy in staging advanced gastric cancer: a multicenter prospective study (PLASTIC-study). *BMC Cancer* 2018; **18**(1): 450. https://doi.org/10.1186/s12885-018-4367-9

52. Atici AE, Cakir T, Reyhan E, Duman M, Ozer I, Ulas M, et al. Preoperative use of PET/CT in patients with colorectal and gastric cancer and its impact on treatment decision making. *Int Surg* 2016; **101**: 318–27. https://doi.org/10.9738/INTSURG-D-16-00006.1

53. Bosch KD, Chicklore S, Cook GJ, Davies AR, Kelly M, Gossage JA, et al. Staging FDG PET-CT changes management in patients with gastric adenocarcinoma who are eligible for radical treatment. *Eur J Nucl Med Mol Imaging* 2020; **47**: 759–67. https://doi.org/10.1007/s00259-019-04429-x

54. Dębiec K, Wydmański J, d'Amico A, Gorczewska I, Krzywon A, Cortez AJ, et al. The application of 18f-FDG-PET/CT in gastric cancerstaging and factors affecting its sensitivity. *Hell J Nucl Med* 2021; **24**: 66–74. https://doi.org/10.1967/s002449912308

55. Duman K, Simsek A, Gorgulu S, Yagci G, Peker Y. The role of 2- [F-18] fluoro 2-deoxy D-glucose positron emission tomography in the preoperative staging of gastric cancer. *Eurasian J Med* 2013; **45**: 149–54. https://doi.org/10.5152/eajm.2013.32

56. Filik M, Kir KM, Aksel B, Soyda Ç, Özkan E, Küçük ÖN, et al. The role of 18F-FDG PET/CT in the primary staging of gastric cancer. *Mol Imaging Radionucl Ther* 2015; **24**: 15–20. https://doi.org/10.4274/mirt.26349

57. Findlay JM, Antonowicz S, Segaran A, El Kafsi J, Zhang A, Bradley KM, et al. Routinely staging gastric cancer with 18F-FDG PET-CT detects additional metastases and predicts early recurrence and death after surgery. *Eur Radiol* 2019; **29**: 2490–98. https://doi.org/10.1007/s00330-018-5904-2

58. Gertsen EC, Brenkman HJF, van Hillegersberg R, van Sandick JW, van Berge Henegouwen MI, Gisbertz SS, et al. 18F-fludeoxyglucose-positron emission tomography/computed tomography and laparoscopy for staging of locally advanced gastric cancer: a multicenter prospective Dutch cohort study (plastic). *JAMA Surg* 2021; **156**(12): e215340. https://doi.org/10.1001/jamasurg.2021.5340

59. Li B, Zheng P, Zhu Q, Lin J. Accurate preoperative staging of gastric cancer with combined endoscopic ultrasonography and PET-CT. *Tohoku J Exp Med* 2012; **228**: 9–16. https://doi.org/10.1620/tjem.228.9

60. Perlaza P, Ortín J, Pagès M, Buxó E, Fernández-Esparrach G, Colletti PM, et al. Should 18F-FDG PET/CT be routinely performed in the clinical staging of locally advanced gastric adenocarcinoma? *Clin Nucl Med* 2018; **43**: 402–10. https://doi.org/10.1097/RLU.0000000000002028

61. Serrano OK, Love C, Goldman I, Huang K, Ng N, Abraham T, et al. The value of FDG-PET in the staging of gastric adenocarcinoma: a single institution retrospective review. *J Surg Oncol* 2016; **113**: 640–46. https://doi.org/10.1002/jso.24190

62. Smyth E, Schöder H, Strong VE, Capanu M, Kelsen DP, Coit DG, et al. A prospective evaluation of the utility of 2-deoxy-2- [(18) F] fluoro-D-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer. *Cancer* 2012; **118**: 5481–88. https://doi.org/10.1002/cncr.27550

63. Mokadem I, Dijksterhuis WPM, van Putten M, Heuthorst L, de Vos-Geelen JM, Haj Mohammad N, et al. Recurrence after preoperative chemotherapy and surgery for gastric adenocarcinoma: a multicenter study. *Gastric Cancer* 2019; **22**: 1263–73. https://doi.org/10.1007/s10120-019-00956-6

64. Markar SR, Mackenzie H, Mikhail S, Mughal M, Preston SR, Maynard ND, et al. Surgical resection of hepatic metastases from gastric cancer: outcomes from national series in England. *Gastric Cancer* 2017; **20**: 379–86. https://doi.org/10.1007/s10120-016-0604-6

65. Aide N, Lasnon C, Kesner A, Levin CS, Buvat I, Iagaru A, et al. New PET technologies-embracing progress and pushing the limits. *Eur J Nucl Med Mol Imaging* 2021; **48**: 2711–26. https://doi.org/10.1007/s00259-021-05390-4

66. Walker MD, Bradley KM, McGowan DR. Evaluation of principal component analysis-based data-driven respiratory gating for positron emission tomography. *Br J Radiol* 2018; **91**: 20170793: 1085: . https://doi.org/10.1259/bjr.20170793